Literature DB >> 25547623

Cat scratch disease during infliximab therapy: a case report and literature review.

Yi Zhou1, Geng Yin, Chunyu Tan, Yi Liu.   

Abstract

Cat scratch disease may occur during etanercept therapy, but there has been no report on infliximab-associated cat scratch disease. We report a case of a 23-year-old woman who developed right inguinal lymph node enlargement following a cat scratch. The patient had received infliximab therapy for spondyloarthropathy. She was successfully managed by discontinuing infliximab and by treatment with moxifloxacin and amikacin.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25547623     DOI: 10.1007/s00296-014-3204-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  12 in total

Review 1.  Recommendations for treatment of human infections caused by Bartonella species.

Authors:  J M Rolain; P Brouqui; J E Koehler; C Maguina; M J Dolan; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

2.  Mesenteric and splenic cat-scratch disease during etanercept therapy.

Authors:  Aurélie Schiffmann; Yves Marie Pers; Cédric Lukas; Bernard Combe; Jacques Morel
Journal:  Rheumatology (Oxford)       Date:  2009-08-18       Impact factor: 7.580

Review 3.  Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.

Authors:  Archana Jain; Jasvinder A Singh
Journal:  Immunotherapy       Date:  2013-03       Impact factor: 4.196

Review 4.  Cat-scratch disease during anti-tumor necrosis factor-alpha therapy: case report and review of the literature.

Authors:  Filipa Osório; Ana Pedrosa; Filomena Azevedo; Paulo Figueiredo; Sofia Magina
Journal:  Int J Dermatol       Date:  2013-04-04       Impact factor: 2.736

5.  Cat-scratch disease. An overview based on a study of 1,200 patients.

Authors:  H A Carithers
Journal:  Am J Dis Child       Date:  1985-11

6.  Cat scratch disease during etanercept therapy.

Authors:  Sylvain Mathieu; Jean-François Vellin; David Poujol; Jean-Michel Ristori; Martin Soubrier
Journal:  Joint Bone Spine       Date:  2007-02-05       Impact factor: 4.929

Review 7.  TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.

Authors:  Marcus W Wiedmann; Joachim Mössner; Christoph Baerwald; Matthias Pierer
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2009-09-01       Impact factor: 2.895

Review 8.  The expanded spectrum of bartonellosis in children.

Authors:  Francesco Massei; Laura Gori; Pierantonio Macchia; Giuseppe Maggiore
Journal:  Infect Dis Clin North Am       Date:  2005-09       Impact factor: 5.982

9.  Tuberculosis during TNF-α inhibitor therapy, despite screening.

Authors:  Regina W Hofland; Steven F T Thijsen; Marc A M T Verhagen; Yolande Schenk; Ailko W J Bossink
Journal:  Thorax       Date:  2013-04-18       Impact factor: 9.139

10.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.